Interview: Lee-Cheng Liu, President & CEO, EirGenix, Taiwan
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
In order to obtain genetic information for analysis and their applications for developing new drugs, precise and qualitative nucleic acid extraction steps are essential. This is Viogene’s primary focus. Viogene provides innovative and cutting-edge nucleic acids extraction technologies and products to allow scientists achieve their goals. Viogene currently has more than 40 nucleic acids extraction products for extracting nucleic acids from various biological sources such as animals, plants, microorganisms. Viogene sells its products in more than 30 countries worldwide.
Another part of Viogene’s research and development program is a platform of G protein coupled receptors (GPCRs) related drugs screening from traditional Chinese medicines (TCMs), GPCRs have proved to be very successful drug targets for more than 30% of marketed drugs which target directly or indirectly on GPCRs, which including the top 100 brand name prescription drugs, however mitigating side effects and increasing potency of GPCRs related drugs are marketed needed, Viogene’s GPCRs new drug screening and discovering programs from TCMs offer new solutions and opportunities for achieving the goals.
No.276, Ta-Tung Rd., Sec.1, Shijr,
New Taipei City, Taiwan
PHONE: 886 2 26472259
FAX: 886 2 26475094
Website: www.viogene.com
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry…
Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent…
Dr Yu-Ray Chen, Professor of Surgery at Chang Gung Memorial Hospital discusses the current state of Taiwan’s healthcare system, highlighting the fact that its current condition is unsustainable in the…
Michael Chiang, the Executive President of Panion & BF Biotech speaks about the incredible growth of the company over the past year, what has contributed to this success and where…
James Wang, Country Managing Partner of Ernst & Young Taiwan explains why Taiwan’s DIG (Diversify-Innovative-Globalize) strategy is crucial for the growth of Taiwan’s economy over the next decade, why biotech…
Full service CRO Choice Pharma moved its operations from Europe to Asia in 2008, and since then the company has thrived. The managing director and business director for the company…
A 2006 article in CommonWealth Magazine detailing the genesis of this company reported that TLC had managed to “break out from the typical dilemma of ordinary biotech firms—to either engage…
The president of Pharmaceutical Industry Technology and Development Center (PITDC) considers the company’s need to remain an international competitor and how to achieve it, the gap in new drug development…
General Manager, Chugai Pharma Taiwan and President of International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA), discusses the continuous price cuts that plague the Taiwan market, and how IRPMA is getting involved…
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
The chairman of Taipei Medical University (TMU) discusses the key challenges TMU has faced over the years, how these challenges will continue to affect the future, and what international accreditation…
See our Cookie Privacy Policy Here
